Product Description
INO-3112 i.e. the combination of VGX-3100 and INO-9012. For Uterine Cervical Neoplasms (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02501278)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Inovio
Company Location: SAN DIEGO CA 92121
Company CEO: Jacqueline E. Shea
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Cervical Cancer|Squamous Cell Carcinoma|Uterine Cancer|Oropharyngeal Cancer|Head and Neck Cancer|Anal Cancer|Anus Cancer|Papilloma|Vaginal Cancer|Penile Cancer|Vulvar Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2018-00914 | P2 |
Terminated |
Anal Cancer|Vulvar Cancer|Vaginal Cancer|Cervical Cancer|Papilloma|Uterine Cancer|Anus Cancer|Penile Cancer |
2022-09-20 |
|
| INO-3112 | P2 |
Withdrawn |
Oropharyngeal Cancer|Squamous Cell Carcinoma |
2021-03-25 |
7% |
| EORTC-1411 | P2 |
Withdrawn |
Cervical Cancer |
2019-05-01 |
|
| HPV-004 | P2 |
Completed |
Uterine Cancer|Cervical Cancer |
2017-09-07 |
|
| HNSCCa | P2 |
Completed |
Head and Neck Cancer|Squamous Cell Carcinoma |
2017-01-23 |